Chemotherapeutic methods for treating low-proliferative disseminated tumor cells

Patent metadata

Field	Value
Publication number	US-11452713-B2
Application number	US-202016845672-A
Country	US
Kind code	B2
Filing date	Apr 10, 2020
Priority date	Feb 29, 2016
Publication date	Sep 27, 2022
Grant date	Sep 27, 2022

Abstract

Disclosed herein are chemotherapeutic methods for the treatment of cancer in humans. In at least one specific embodiment, the method can include administering a therapeutic effective amount of one or more p38 inhibitor compound or salt thereof to a human. The method can also include administering a therapeutic effective of one or more IL-6 inhibitor or one or more IL-6 receptor inhibitor or salt thereof to the human. The method can also include administering a therapeutic effective amount of one or more cytotoxic compound or salt thereof to the human.

First claim

What is claimed is:

1. A method of treating a subject having TWIST1 positive low-proliferative disseminated tumor cells (lpDTCs), comprising:
administering to the subject a therapeutic effective amount of one or more anti-IL-6 receptor (IL-6R) antibodies, and
administering to the subject a therapeutic effective amount of one or more anticancer cytotoxic drugs or salts thereof,
wherein the one or more anti-IL-6 receptor antibodies are administered about 1 hour to about 1 week prior to administration of the one or more cytotoxic drugs or salts thereof, and
wherein administration of the one or more anti-IL-6 receptor (IL-6R) antibodies prior to administration of the one or more cytotoxic drugs or salts thereof increases sensitivity of the lpDTCs to the one or more cytotoxic drugs or salts thereof.

2. The method of claim 1 , wherein the one or more cytotoxic drugs are selected from the group consisting of: bendamustine, busulfan, carmustine, chlorambucil, cyclophosphamide, dacarbazine, ifosfamide, melphalan, procarbazine, streptozocin, temozolomide, asparaginase, capecitabine, cytarabine, 5-fluoro uracil, fludarabine, gemcitabine, methotrexate, pemetrexed, raltitrexed, actinomycin D, dactinomycin, bleomycin, daunorubicin, doxorubicin, doxorubicin (pegylated liposomal), epirubicin, idarubicin, mitomycin, mitoxantrone, etoposide, docetaxel, irinotecan, paclitaxel, topotecan, vinblastine, vincristine, vinorelbine, carboplatin, cisplatin, oxaliplatin, alemtuzamab, bacullus calmette-guerin, bevacizumab, cetuximab, denosumab, erlotinib, gefitinib, imatinib, interferon, ipilimumab, lapatinib, panitumumab, rituximab, sunitinib, sorafenib, temsirolimus, Trastuzumab, clodronate, ibandronic acid, pamidronate, zolendronic acid, anastrozole, abiraterone, amifostine, bexarotene, bicalutamide, buserelin, cyproterone, degarelix, exemestane, flutamide, and folinic acid.

3. The method of claim 1 , wherein the lpDTCs are derived from a cancer selected from the group consisting of: breast cancer, pancreas cancer, skin cancer, bone cancer, prostate cancer, liver cancer, lung cancer, brain cancer, cancer of the larynx, gallbladder, pancreas, rectum, parathyroid, thyroid, adrenal, neural tissue, head and neck, colon, stomach, bronchi, kidneys, basal cell carcinoma, squamous cell carcinoma, metastatic skin carcinoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant fibrous histiocytoma, fibrosarcoma, multiple myeloma, reticulum cell sarcoma, myeloma, giant cell tumor, small-cell lung tumor, gallstones, islet cell tumor, primary brain tumor, acute and chronic lymphocytic and granulocytic tumors, hairy-cell tumor, adenoma, hyperplasia, medullary carcinoma, pheochromocytoma, mucosal neuromas, intestinal ganglioneuromas, hyperplastic corneal nerve tumor, marfanoid habitus tumor, Wilm's tumor, seminoma, ovarian tumor, leiomyomater tumor, cervical dysplasia and in situ carcinoma, neuroblastoma, glioblastoma, retinoblastoma, soft tissue sarcoma, malignant carcinoid, topical skin lesion, mycosis fungoide, rhabdomyosarcoma, Kaposi's sarcoma, osteogenic and other sarcoma, malignant hypercalcemia, renal cell tumor, polycythemia vera, adenocarcinoma, glioblastoma multiforma, leukemias, lymphomas, malignant melanomas, and epidermoid carcinomas.

4. The method of claim 1 , wherein the one or more IL-6 pathway inhibitor compounds or salts thereof is administered about 3 days prior to administering the one or more cytotoxic drugs.

5. The method of claim 1 , wherein the anti-IL-6R antibody comprises a polyclonal antibody, a monoclonal antibody, a chimeric antibody, or a humanized antibody.

6. The method of claim 5 , wherein the anti-IL-6R antibody is selected from the group consisting of: tocilizumab, sarilumab, and ALX-0061.

7. The method of claim 1 , wherein the lpDTCs are located in lung or bone marrow.

8. The method of claim 1 , wherein the lpDTCs are chemoresistant.

Assignees

• Univ Florida

Inventors

• Tran David

Classifications

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• A61K31/12

  Ketones · CPC title

• A61K31/421 Primary

  1,3-Oxazoles, e.g. pemoline, trimethadione · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K47/6835

  the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site · CPC title